Diabetes Care Drugs Industry Overview
|Study Period:||2018 - 2028|
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
|CAGR:||> 3 %|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and its growth?
Diabetes Care Drugs Market Analysis
The Diabetes Care Drugs Market is expected to register a CAGR greater than 3% over the forecast period, 2022-2027.
Diabetes is a chronic, life-threatening disease with no known cure. As per the World Health Organization, there are over 400 million people with diabetes across the world, and its treatment constitutes around 12% of the total healthcare expenditure on a global scale. It has emerged as a global epidemic and afflicted millions worldwide. The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs initiated by various health organizations related to health awareness. Currently, about 10% of all diabetes cases are Type-1 and the remaining are Type-2.
As of 2021, North America accounted for a major share of the market, followed by Asia-Pacific. The increase in the number of diabetes patients is primarily due to increasing obesity among people caused by unhealthy diets and sedentary lifestyles. The market in Asia-Pacific is mainly driven by increasing demand for diabetes drugs from China and India. Currently, China has over 129 million diabetes patients, while the number of diabetes patients in India is expected to reach 82 million by 2027.
Based on drugs, the insulin segment holds a significant share in the market. Over 100 million people around the world need insulin, including all the people suffering from Type-1 diabetes and between 10% and 25% of people with Type-2 diabetes. Production of insulin is very complex, and there are very few companies in the market that manufacture insulin. Due to this, there is high competition between these manufacturers, who always strive to meet the patient’s needs to supply the best-quality insulin.
Diabetes Care Drugs Industry Segments
Diabetes or diabetes mellitus describes a group of metabolic disorders characterized by a high blood sugar level in a person. With diabetes, the body either does not produce enough insulin or the body's cells do not respond properly to insulin, or both. The diabetes care drugs market is segmented by drugs into Insulin (Basal or Long-Acting, Bolus or Fast-Acting, Traditional Human Insulin Drugs, and Insulin Biosimilars), Oral Anti-Diabetic Drugs (Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors), Non-Insulin Injectable Drugs (GLP-1 Receptor Agonists, and Amylin Analogue), and Combination Drugs (Combination Insulin, Oral Combination).
Diabetes Care Drugs Market Trends
This section covers the major market trends shaping the Diabetes Care Drugs Market according to our research experts:
Insulin Drugs is Having the Highest Market Share in 2021
The insulin segment is expected to increase with a CAGR of over 3% during the forecast period, mainly due to the demand from the Type-1 diabetes population, which was more than 58 million by the end of 2027.
According to the International Diabetes Federation, diabetes patients spent USD 966 billion in 2021, of which, a major chunk was spent by Type-1 diabetes patients on insulin drugs. Few Type-2 diabetes patients also depend on insulin. Although only 10% of the diabetes population is Type-1, their intake of insulin is higher in them. Demand for insulin is driven by an increase in awareness about the benefits of insulin for diabetes patients, especially in emerging economies. Other factors, such as rapid development in insulin delivery systems, drug and analog development by major companies, and the rise in the geriatric and obese population, may fuel the growth of the insulin market.
To understand key trends, Download Sample Report
North America is Expected to Dominate the Diabetes Drugs Market.
North America dominates the global insulin therapeutics market, owing to the high prevalence of diabetes in the region because of the sedentary lifestyle and the launch of new drugs in the region. The United States is expected to grow tremendously during the forecast period, owing to factors, such as the high prevalence of obesity and increasing awareness regarding diabetes care in the region. North America remained the largest market for insulin drugs, primarily due to high demand from the United States.
In January 2020, Novo Nordisk announced that the US Food and Drug Administration (FDA) had approved Fiasp (insulin aspart injection) 100 u/mL for use as a new mealtime insulin option for children with diabetes. Such developments are expected to increase the sales of Fiasp during the forecast period.
Thus, owing to the above factors it is expected to drive the market growth over the forecast period.
To understand geography trends, Download Sample Report
Diabetes Care Drugs Market Competitor Analysis
The diabetes drugs market is moderately fragmented, with few significant and generic players. The insulin drugs and Sglt-2 drugs market are dominated by a few major players, like Novo-Nordisk, Sanofi, AstraZeneca, and Bristol Myers Squibb. The market for oral drugs, like Sulfonylureas and Meglitinides, comprises more generic players. The intensity of competition among the players is high, as each player is striving to develop new drugs and offer them at competitive pricing. Furthermore, to increase their market shares, players are tapping into new markets, especially emerging economies where the demand is very high compared to the supply.
Diabetes Care Drugs Market Top Players
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Diabetes Care Drugs Market Recent Developments
- In May 2022, the U.S. Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro was effective at improving blood sugar and was more effective than the other diabetes therapies with which it was compared in clinical studies.
- In 2021, the U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product Semglee (insulin glargine). Semglee is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes. Approval of these insulin products can provide patients with additional safe, high-quality, and potentially cost-effective options for treating diabetes.
Diabetes Care Drugs Market Report - Table of Contents
1.1 Study Assumptions
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Drugs
5.1.1 Oral Anti-diabetic drugs (Value and Volume 2016-2027)
18.104.22.168 Alpha-glucosidase Inhibitors
22.214.171.124 Dopamine -D2 Receptor Agonist
126.96.36.199.1 Cycloset (Bromocriptin)
188.8.131.52 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitors
184.108.40.206.1 Invokana (Canagliflozin)
220.127.116.11.2 Jardiance (Empagliflozin)
18.104.22.168.3 Farxiga/Forxiga (Dapagliflozin)
22.214.171.124.4 Suglat (Ipragliflozin)
126.96.36.199 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
188.8.131.52.1 Januvia (Sitagliptin)
184.108.40.206.2 Onglyza (Saxagliptin)
220.127.116.11.3 Tradjenta (Linagliptin)
18.104.22.168.4 Vipidia/Nesina (Alogliptin)
22.214.171.124.5 Galvus (Vildagliptin)
5.1.2 Insulin (Value and Volume 2016-2027)
126.96.36.199 Basal or Long-acting Insulin
188.8.131.52.1 Lantus (Insulin Glargine)
184.108.40.206.2 Levemir (Insulin Detemir)
220.127.116.11.3 Toujeo (Insulin Glargine)
18.104.22.168.4 Tresiba (Insulin Degludec)
22.214.171.124.5 Basaglar (Insulin Glargine)
126.96.36.199 Bolus or Fast-acting Insulin
188.8.131.52.1 NovoRapid/Novolog (Insulin Aspart)
184.108.40.206.2 Humalog (Insulin Lispro)
220.127.116.11.3 Apidra (Insulin Glulisine)
18.104.22.168 Traditional Human Insulin
22.214.171.124 Biosimilar Insulin
126.96.36.199.1 Insulin Glargine Biosimilars
188.8.131.52.2 Human Insulin Biosimilars
5.1.3 Non-insulin Injectable Drug (Value and Volume 2016-2027)
184.108.40.206 GLP-1 Receptor Agonists
220.127.116.11.1 Victoza (Liraglutide)
18.104.22.168.2 Byetta (Exenatide)
22.214.171.124.3 Bydureon (Exenatide)
126.96.36.199.4 Trulicity (Dulaglutide)
188.8.131.52.5 Lyxumia (Lixisenatide)
184.108.40.206 Amylin Analogue
220.127.116.11.1 Symlin (Pramlintide)
5.1.4 Combination Drug (Value and Volume 2016-2027)
18.104.22.168 Combination Insulin
22.214.171.124.1 NovoMix (Biphasic Insulin Aspart)
126.96.36.199.2 Ryzodeg (Insulin Degludec and Insulin Aspart)
188.8.131.52.3 Xultophy (Insulin Degludec and Liraglutide)
184.108.40.206 Oral Combination
220.127.116.11.1 Janumet (Sitagliptin and Metformin HCl)
5.2.1 North America
18.104.22.168 United States (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 Canada (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Rest of North America (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 France (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 Germany (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Italy (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 Spain (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 United Kingdom (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Russia (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 Rest of Europe (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
5.2.3 Latin America
184.108.40.206 Mexico (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Brazil (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 Rest of Latin America (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 Japan (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 South Korea (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 China (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 India (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Australia (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 Vietnam (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 Malaysia (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Indonesia (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 Philippines (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 Thailand (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Rest of Asia-Pacific (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
5.2.5 Middle-East and Africa
18.104.22.168 Saudi Arabia (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 Iran (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Egypt (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
18.104.22.168 Oman (Value and Volume 2016-2027)
22.214.171.124.1 Oral Anti-diabetic Drugs
126.96.36.199.3 Non-insulin Injectable Drugs
188.8.131.52.4 Combination Drugs
184.108.40.206 South Africa (Value and Volume 2016-2027)
220.127.116.11.1 Oral Anti-diabetic Drugs
18.104.22.168.3 Non-insulin Injectable Drugs
22.214.171.124.4 Combination Drugs
126.96.36.199 Rest of Middle-East and Africa (Value and Volume 2016-2027)
188.8.131.52.1 Oral Anti-diabetic Drugs
184.108.40.206.3 Non-insulin Injectable Drugs
220.127.116.11.4 Combination Drugs
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population (2016-2027)
6.2 Type-2 Diabetes Population (2016-2027)
7. COMPETITIVE LANDSCAPE
7.1 Company Profiles
7.1.1 Novo Nordisk
7.1.3 Eli Lilly and Company
7.1.6 Bristol Myers Squibb
7.1.7 Boehringer Ingelheim
7.1.10 Johnson & Johnson
7.1.11 Merck & Co.
7.1.13 Astellas Pharma
7.1.14 Teva Pharmaceuticals
7.2 Company Share Analysis
7.2.1 Insulin Drugs
18.104.22.168 Novo Nordisk
22.214.171.124 Eli Lilly and Company
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Diabetes Care Drugs Market Research FAQs
What is the study period of this market?
The Diabetes Care Drugs Market is studied from 2018 - 2028.
What is the growth rate of Diabetes Care Drugs Market?
The Diabetes Care Drugs Market is growing at a CAGR of >3% over the next 5 years.
What is Diabetes Care Drugs Market size in 2018?
The Diabetes Care Drugs Market is valued at 81 Billion USD in 2018.
What is Diabetes Care Drugs Market size in 2028?
The Diabetes Care Drugs Market is valued at 91 Billion USD in 2028.
Which region has highest growth rate in Diabetes Care Drugs Market?
Asia Pacific is growing at the highest CAGR over 2018 - 2028.
Which region has largest share in Diabetes Care Drugs Market?
North America holds highest share in 2021.
Who are the key players in Diabetes Care Drugs Market?
Novo Nordisk, Sanofi, AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company are the major companies operating in Diabetes Care Drugs Market.
Diabetes Care Drugs Industry Reports
In-depth industry statistics and market share insights of the Diabetes Care Drugs sector for 2020, 2021, and 2022. The Diabetes Care Drugs research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the Diabetes Care Drugs report PDF.